0000899243-18-002333.txt : 20180130 0000899243-18-002333.hdr.sgml : 20180130 20180130210133 ACCESSION NUMBER: 0000899243-18-002333 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180126 FILED AS OF DATE: 20180130 DATE AS OF CHANGE: 20180130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shaff Eric D. CENTRAL INDEX KEY: 0001643734 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 18560726 MAIL ADDRESS: STREET 1: C/O SERES HEALTH, INC. STREET 2: 161 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-01-26 0 0001609809 Seres Therapeutics, Inc. MCRB 0001643734 Shaff Eric D. C/O SERES THERAPEUTICS, INC. 200 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 See Remarks COMMON STOCK 2018-01-26 4 M 0 8000 A 8000 D COMMON STOCK 2018-01-26 4 S 0 2780 11.02 D 5220 D RESTRICTED STOCK UNITS 2018-01-26 4 M 0 8000 0.00 D COMMON STOCK 8000 32000 D STOCK OPTION (RIGHT TO BUY) 10.42 2018-01-30 4 A 0 120000 0.00 D 2028-01-29 COMMON STOCK 120000 120000 D Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020. The Option will vest as to 25% of the shares on January 30, 2019. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Chief Financial Officer and EVP /s/ Thomas J. DesRosier, Attorney-in-Fact 2018-01-30